Catalog No.
YHC98301
Expression system
E. coli
Species
Homo sapiens (Human)
Protein length
Ile1203-Ser1426
Predicted molecular weight
26.23 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
P13569
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
Cystic fibrosis transmembrane conductance regulator, CFTR, ATP-binding cassette sub-family C member 7, Channel conductance-controlling ATPase, 5.6.1.6, cAMP-dependent chloride channel, CFTR, ABCC7
Elexacaftor/Tezacaftor/Ivacaftor Supports Treatment for CF with ΔI1023-V1024-CFTR., PMID:40508114
Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis: A Review of Registry-Based Evidence., PMID:40507740
Differential Expression and Microsystem Physiology Reveal Predominant and Drug Reversible CFTR-Related Defects in Idiopathic Pancreatitis., PMID:40502040
CFTR mutation leads to intrinsic dysfunction in neutrophils from people with Cystic Fibrosis., PMID:40501645
Exploring serum and glucocorticoid-regulated kinase 1: A promising target for COVID-19 and atrial fibrillation treatment., PMID:40496592
Cellular imbalance in proximal and distal lung of CFTR-/- sheep in utero and at birth., PMID:40495135
Systemic in utero gene editing as a treatment for cystic fibrosis., PMID:40493185
The role of Bifidobacterium animalis QC08 in antibiotic-associated diarrhea in mice., PMID:40492055
Glucagon-like peptide-1 receptor agonists in adults with cystic fibrosis-related diabetes: Rationale and emerging evidence., PMID:40490408
Vitamin D status in young adults with cystic fibrosis on highly effective CFTR modulator therapy., PMID:40484046
Australasian guideline for the performance of sweat chloride testing 3rd edition: to support cystic fibrosis screening, diagnosis and monitoring., PMID:40476459
Real-world improvement in ultra-low-dose thoracic computed tomography scores, systemic inflammatory markers and patient-reported outcome measures after elexacaftor/tezacaftor/ivacaftor treatment., PMID:40470159
Single cell profiling of human airway identifies tuft-ionocyte progenitor cells displaying cytokine-dependent differentiation bias in vitro., PMID:40467553
State-of-the-Art Review: Transformative Changes in the Care of People With Cystic Fibrosis: Implications for Infectious Diseases Specialists., PMID:40465484
Executive Summary: State-of-the-Art Review: Transformative Changes in the Care of People With Cystic Fibrosis-Implications for Infectious Diseases Specialists., PMID:40465483
Cystic fibrosis in Vietnam and Southeast Asia: underdiagnosis and genetic spectrum., PMID:40465100
ENaC contributes to macrophage dysfunction in cystic fibrosis., PMID:40454714
The relationship between cancer risk and cystic fibrosis: the role of CFTR in cell growth and cancer development., PMID:40438286
In-depth analysis of cystic fibrosis cases caused by CFTR gene variation and research on the prediction and simulation of the impact on protein function., PMID:40433478
Deleterious effect of Pseudomonas aeruginosa on F508del-CFTR rescued by elexacaftor/tezacaftor/ivacaftor is clinical strain-dependent in patient-derived nasal cells., PMID:40432819
Identification and Characterization of a Rare Exon 22 Duplication in CFTR in Two Families., PMID:40429633
Case Study: Genetic and In Silico Analysis of Familial Pancreatitis., PMID:40428425
Lipid transporters E-Syt3 and ORP5 regulate epithelial ion transport by controlling phosphatidylserine enrichment at ER/PM junctions., PMID:40425857
Risk of pancreatic cancer in cystic fibrosis and cystic fibrosis transmembrane conductance regulator (CFTR) germline variants: A retrospective cohort study., PMID:40423702
Ivacaftor-tezacaftor-elexacaftor, tezacaftor-ivacaftor and lumacaftor-ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation., PMID:40418577
Relationship between sweat chloride and pulmonary function in healthy young adults - a single-center, pilot study., PMID:40414315
Impact of availability of a highly effective Cystic Fibrosis treatment (elexacaftor/tezacaftor/ivacaftor) on lung transplant waitlist and lung transplantation trends in the US., PMID:40409741
Population Pharmacokinetics of Elexacaftor, Tezacaftor and Ivacaftor in a Real-World Cohort of Adults with Cystic Fibrosis., PMID:40405059
Pharmacokinetics of Ivacaftor, Tezacaftor, Elexacaftor, and Lumacaftor in Special Cystic Fibrosis Populations: A Systematic Review., PMID:40399734
ER tubular body: an ER-derived compartment for redirecting autophagy to secretory functions., PMID:40390263
Effect of cystic fibrosis modulator therapies on serum levels of fat-soluble vitamins., PMID:40386324
Cyclodextrin-Based Inclusion Complexes Improve the In Vitro Solubility and Pharmacokinetics of Ivacaftor Following Oral Administration in Mice., PMID:40379997
LONGITUDE: An observational study of the long-term effectiveness of elexacaftor/tezacaftor/ivacaftor in people aged ≥12 years with cystic fibrosis using data from the United Kingdom Cystic Fibrosis Registry - 2-year analysis., PMID:40379539
Improvement of intestinal inflammation after treatment with CFTR modulators in cystic fibrosis patients., PMID:40379512
Dietary intake remains unchanged while nutritional status improves in children and adults with cystic fibrosis on Elexacaftor/Tezacaftor/Ivacaftor., PMID:40378731
Advances in the treatment of cystic fibrosis: CFTR modulators., PMID:40374426
Generation of gastric proton pump atp4a knockouts in Astyanax mexicanus: a fish model for insights into the mechanisms of acidification by oxynticopeptic cells., PMID:40372704
Ivacaftor affects the susceptibility of standard-of-care drugs used to treat Mycobacterium abscessus lung disease., PMID:40372084
Evidence of secondary Notch signaling within the rat small intestine., PMID:40371707
[Transition in patients with cystic fibrosis and asthma]., PMID:40369362
20 years of the Montreal Cystic Fibrosis Related Diabetes Screening Cohort: key insights., PMID:40368427
Managing an ageing cystic fibrosis population: challenges and priorities., PMID:40368426
Crushing Elexacaftor/Tezacaftor/Ivacaftor Oral Granules for Gastrostomy Tube Administration., PMID:40365926
Clinical Disorders in Cystic Fibrosis That Affect Emergency Procedures-A Case Report and Review., PMID:40364218
A Liquid Chromatography-Tandem Mass Spectrometry Method for the Quantification of Cystic Fibrosis Drugs (Caftors) in Plasma and Its Application for Therapeutic Monitoring., PMID:40363673
Interactions of CFTR and Arylsulfatase B (ARSB; N-acetylgalactosamine-4-sulfatase) in Prostate Carcinoma., PMID:40362587
Recombinant Adeno-Associated Virus Vector Mediated Gene Editing in Proliferating and Polarized Cultures of Human Airway Epithelial Cells., PMID:40359132
Sweat conductivity test - can it be a cheaper alternative to sweat chloride analysis for diagnosis of cystic fibrosis in low resource setting?, PMID:40347500
Elexacaftor/Tezacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients With Cystic Fibrosis., PMID:40347054
Glycan-Modified Cellular Nanosponges for Enhanced Treatment of Cholera Toxin-Induced Secretory Diarrhea., PMID:40340322
For research use only. Not for human or drug use.
